In particular, CHD7 overexpression in breast cancer is more prevalent in aggressive subtypes, where it is combined with the activation of NRAS and MYCN oncogenes and correlates with high tumor grade and poor prognosis; conversely, CHD7 depletion in human breast cancer cell lines is sufficient to inhibit cell proliferation and downregulate the expression of CHD7 target genes, including NRAS oncogene (Chu et al., 2017). This evidence concerns the gene NRAS and neoplasm.